News & SEC Filings

View the latest news and SEC filings

News

Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD population LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces four oral presentations and

One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces one oral presentation

Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona

LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44 th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m.

SEC Filings

Date Form Filing Group

September 13, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

September 13, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

September 11, 2024

Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

144

Other

September 11, 2024

Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

144

Other

August 28, 2024

An amendment to a SC 13D filing

SC 13D/A

Other

August 14, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

August 14, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

August 14, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

August 12, 2024

Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

144

Other

Developing novel therapeutics for respiratory diseases

Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.